Tumor Biology

, Volume 36, Issue 11, pp 8301–8308 | Cite as

Effect of nisin and doxorubicin on DMBA-induced skin carcinogenesis—a possible adjunct therapy

  • Simran Preet
  • Sanjay Bharati
  • Anshul Panjeta
  • Rupinder Tewari
  • Praveen Rishi
Research Article

Abstract

In view of the emergence of multidrug-resistant cancer cells, there is a need for therapeutic alternatives. Keeping this in mind, the present study was aimed at evaluating the synergism between nisin (an antimicrobial peptide) and doxorubicin (DOX) against DMBA-induced skin carcinogenesis. The possible tumoricidal activity of the combination was evaluated in terms of animal bioassay observations, changes in hisotological architecture of skin tissues, in situ apoptosis assay (TUNEL assay) and in terms of oxidant and antioxidant status of the skin tissues. In vivo additive effect of the combination was evidenced by larger decreases in mean tumour burden and tumour volume in mice treated with the combination than those treated with the drugs alone. Histological observations indicated that nisin-DOX therapy causes chromatin condensation and marginalisation of nuclear material in skin tissues of treated mice which correlated well with the results of TUNEL assay wherein a marked increase in the rate of apoptosis was revealed in tissues treated with the combination. A slightly increased oxidative stress in response to the adjunct therapy as compared to dox-alone-treated group was revealed by levels of lipid peroxidation (LPO) and nitrite generation in skin tissue-treated mice. An almost similar marginal enhancement in superoxide dismutase levels corresponding with a decrease in catalase activity could also be observed in nisin + DOX-treated groups as compared to nisin and dox-alone-treated groups. These results point towards the possible use of nisin as an adjunct to doxorubicin may help in developing alternate strategies to combat currently developing drug resistance in cancer cells.

Keywords

Nisin Doxorubicin Adjunct Skin cancer Anti-cancer peptide 

Notes

Acknowledgments

The authors are grateful to Dr. B.N. Dutta for his support in histopthological analysis and Dr. S.N Sanyal for sharing his immense knowledge with us.

Authors’ contributions

Conceived and designed the study: SP. Performed lab analysis: SB and AP. Performed data analysis: SB. Wrote the manuscript: SP and PR. Provided lab facilities and helped in data analysis: SP, PR and RT.

Conflict of interest

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Kakde D, Jain D, Shrivastava V, Kakde R, Patil AT. Cancer therapeutics—opportunities, challenges and advances in drug delivery. J App Pharm Sci. 2011;1:1.Google Scholar
  2. 2.
    Aly A, Mullins CD, Hussain A. Understanding heterogeneity of treatment effect in prostate cancer. Curr Opin Oncol. 2015;27:209–16.CrossRefPubMedGoogle Scholar
  3. 3.
    Busch CJ, Tribius S, Schafhausen P, Knecht R. The current role of systemic chemotherapy in the primary treatment of head and neck cancer. Cancer Treat Rev. 2015;41:217–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Coward JI, Middleton K, Murphy F. The new perspectives on targeted therapy in ovarian cancer. Int J Wom Health. 2015;7:189–03.CrossRefGoogle Scholar
  5. 5.
    Hoskin DW, Ramamoorthy A. Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta Biomembr. 2008;1778:357–75.CrossRefGoogle Scholar
  6. 6.
    Schweizer F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur J Pharm. 2009;625:190–4.CrossRefGoogle Scholar
  7. 7.
    Bhutia SK, Maiti TK. Targeting tumours with peptides from natural sources. Trends Biotechnol. 2008;26:210–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Wei XQ, Ma HQ, Liu AH, Zhang YZ. Synergistic anticancer activity of 5-aminolevulinic acid photodynamic therapy in combination with low-dose cisplatin on Hela cells. Asian Pac J Cancer Prev. 2013;14:3023–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Sylvester PW, Wali VB, Bachawal SV, Shirode AB, Ayoub NM, Akl MR. Tocotrienol combination therapy results in synergistic anticancer response. Front Biosci (Landmark Ed). 2011;1:3183–95.CrossRefGoogle Scholar
  10. 10.
    Jay JM. Modern Food Microbiology. 6th ed. Gaithersburg: Aspen Publishers Inc; 2000. p. 679.CrossRefGoogle Scholar
  11. 11.
    Joo NE, Ritchie K, Kamarajan P, Miao D, Kapila YL. Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumourigenesis via CHAC1. Cancer Med. 2012;1:295–05.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Arora N, Koul A, Bansal MP. Chemopreventive activity of Azadirachta indica on two-stage skin carcinogenesis in murine model. Phytother Res. 2011;25:408–16.PubMedGoogle Scholar
  13. 13.
    Subapriya R, Nagini S. Medicinal properties of neem leaves: a review. Curr Med Chem Anti Cancer Agents. 2005;5:149–56.CrossRefPubMedGoogle Scholar
  14. 14.
    Bharati S, Rishi P, Koul A. Azadirachta indica modulates electrical properties and type of cell death in NDEA-induced hepatic tumours. Cell Biochem Bioph. 2014;70:383–90.CrossRefGoogle Scholar
  15. 15.
    Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem J. 1966;99:667–76.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Rishi P, Preet S, Bharrhan S, Verma I. In vitro and in vivo synergistic effects of cryptdin- 2 and ampicillin against Salmonella. Antimicrob Agents Chemother. 2011;55:4176–82.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Green LC et al. Analysis of nitrate, nitrite and 15N nitrate in biological fluids. Anal Biochem. 1982;126:131–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Luck H. Catalase. In: Bergmeyer HU, editor. Methods of enzymatic analysis. New York: Academic Press; 1963. p. 885–88.Google Scholar
  19. 19.
    Lowry OH, Rosenbrough NJ, Farr AL, Randell RJ. Protein measurement with Folin’s phenol reagent. J Biol Chem. 1951;193:265–75.PubMedGoogle Scholar
  20. 20.
    Diwan BA, Kasprzak KS, Anderson LM. Promotion of dimethylbenzanthracene-initiated mammary carcinogenesis by iron in female Sprague–Dawley rats. Carcinogenesis. 1997;18:1757–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow–derived cells contributes to skin carcinogenesis. Cell. 2000;103:481–90.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Padmavathi B, Upreti M, Singh V, Rao AR, Singh RP, Rath PC. Chemoprevention by Hippophae rhamnoides: effects on tumourigenesis, phase II and antioxidant enzymes, and IRF-1 transcription factor. Nutr Cancer. 2005;51(1):59–67.CrossRefPubMedGoogle Scholar
  23. 23.
    Yokochi T, Robertson KD. Doxorubicin inhibits DNMT1 resulting in conditional apoptosis. Mol Pharmacol. 2004;66:1415–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Aldieri E, Bergandi L, Riganti C, Costamagna C, Bosia A, Ghigo D. Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation. Toxicol Appl Pharmacol. 2002;185:85–90.CrossRefPubMedGoogle Scholar
  25. 25.
    Tamir S, Tannenbaum SR. The role of nitric oxide (NO) in the carcinogenic process. Biochim Biophys Acta. 1996;1288:F31–6.PubMedGoogle Scholar
  26. 26.
    Murphy MP. Nitric oxide and cell death. Biochim Biophys Acta. 1999;1411:401–14.CrossRefPubMedGoogle Scholar
  27. 27.
    Bartoli GM, Galeotti T. Growth-related lipid peroxidation in tumour microsomal membranes and mitochondria. Biochimica et Biophysica Acta (BBA)—Lipids and Lipid. Metabolism. 1979;574:537–41.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Simran Preet
    • 1
  • Sanjay Bharati
    • 1
  • Anshul Panjeta
    • 1
  • Rupinder Tewari
    • 2
  • Praveen Rishi
    • 3
  1. 1.Department of Biophysics, Basic Medical Sciences Block-2Panjab UniversityChandigarhIndia
  2. 2.Department of Microbial TechnologyPanjab UniversityChandigarhIndia
  3. 3.Department of Microbiology, Basic Medical Sciences Block-1Panjab UniversityChandigarhIndia

Personalised recommendations